Navigation Links
PET predicts outcomes for patients with cervical spinal cord compression
Date:9/4/2013

Reston, Va. (September 4, 2013) For patients with degenerative cervical myelopathy, imaging with 18F-FDG positron emission tomography (PET) could act as a marker for a potentially reversible phase of the disease in which substantial clinical improvement can be achieved. According to research published in the September issue of The Journal of Nuclear Medicine, patients who exhibited hypermetabolism at the point of compression in their spine experienced improved outcomes after undergoing decompressive surgery.

Cervical spinal stenosis is a condition in which the spinal canal narrows in the neck. While many patients lack symptoms, once symptoms appear, it usually indicates the presence of myelopathy. This compression can lead to progressive neurologic deficits, such as numbness, weakness or tingling in a leg, foot, arm or hand.

In the study "Hypermetabolism in 18F-FDG PET Predicts Favorable Outcome Following Decompressive Surgery in Patients with Degenerative Cervical Myelopathy," researchers aimed to assess the regional changes of glucose metabolism of the cervical spinal cord using 18F-FDG PET. "To date, experiences with 18F-FDG PET in symptomatic patients with degenerative cervical spine stenosis and consecutive compressive myelopathy are very limited," said Norbert Galldiks, MD, one of the lead researchers of the study. "In the present study, we present the results of preoperative magnetic resoncance imaging and 18F-FDG PET imaging and postoperative follow-up imaging 12 months after decompressive surgery. Imaging findings were correlated with the clinical outcome."

Researchers observed two significantly different patterns of 18F-FDG uptake among the 20 study participants prior to surgeryapproximately half of the patients had increased 18F-FDG uptake at the site of spinal cord compression and were classified as myelopathy type 1, while the other half had inconspicuous 18F-FDG uptake and were classified as myelopathy type 2. Post-operatively, those with myelopathy type 1 had a marked decrease in 18F-FDG uptake, while myelopathy type 2 patients had only a moderate decline in uptake.

The overall outcome in myelopathy type 1 patients was favorable, and the patients showed significant improvement on their functional status assessment. In contrast, there was no significant clinical change in patients with inconspicuous 18F-FDG uptake.

"A hypermetabolism of the cervical spinal cord at the level of cervical spine stenosis as indicated by a locally increased 18F-FDG uptake seems to be a marker for a potentially reversible phase of a compression-induced cervical myelopathy," explained Galldiks. "The lesion of the spinal cord seems to be predominantly functional. Presence of this metabolic pattern reflects the time frame when decompressive surgery can lead to substantial clinical improvement. In order to stratify eligible patients for decompressive surgery, our findings may help to implement 18F-FDG PET investigations of the cervical spine in clinical routine."


'/>"/>

Contact: Susan Martonik
smartonik@snmmi.org
703-652-6773
Society of Nuclear Medicine
Source:Eurekalert

Related medicine news :

1. Protein-based urine test predicts kidney transplant outcomes
2. Low childhood conscientiousness predicts adult obesity
3. Novus Medical Detox Predicts Taxpayer-Paid Drug Abuse Amid Medicare Fraud, Urges Federal Regulations
4. Study predicts potential surge in medically-attended injuries
5. Biomarker predicts risk of breast cancer recurrence after tamoxifen treatment
6. The Tourism Authority of Thailand Predicts 1.42 Million Japanese Visitors in 2013 Following This Year’s Thai Tourism Festival in Tokyo
7. A statistical model predicts the number of goals for each footballer
8. Simple frailty test predicts death, hospitalization for kidney dialysis patients
9. Genetic diversity within tumors predicts outcome in head and neck cancer
10. Study shows that bedtime regularity predicts CPAP compliance
11. Warning system predicts outbreaks of dengue fever
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... ... The American Board of Family Medicine's (ABFM) Board of Directors has selected ... Dr. James C. Puffer upon his retirement. Dr. Newton will serve in the position ... the end of 2018. Upon assuming the role of President and CEO on January ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Hannah Randall, PharmD ‘17, and Jennifer Huggins, PharmD ’17, along with clinical ... the primary prevention of cardiovascular diseases during the 15th Annual Women’s Health ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Many families ... However, many long-term care insurance companies have a waiver for care if the client ... elimination period, when the family pays for care, is often waived, so the benefits ...
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th Annual ... in Milford, NJ. This free event, sponsored by Global Healthcare Management’s CEO, Jon ... fun run is geared towards children of all ages; it is a non-competitive, non-timed ...
(Date:10/13/2017)... , ... October 13, 2017 , ... ... and Agile Software Development, has been awarded a contract by the Center for ... Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in a ...
Breaking Medicine News(10 mins):
(Date:9/22/2017)... SAN DIEGO , Sept. 22, 2017 ... ll medical device is now successfully helping those with ... Union. Fibromyalgia diagnosed Amanda in ... getting dressed and washing my hair, experiencing no sleep ... body in painful spasm… I cannot recommend [the AVACEN ...
(Date:9/18/2017)... PROVIDENCE, R.I. , Sept. 18, 2017 ... in the fields of bioinformatics and immune ... to develop a protective avian influenza A (H7N9) vaccine. ... is distantly related to seasonal influenza and ... approaches, which rely on prior exposure to be ...
(Date:9/12/2017)... Sept. 12, 2017  ValGenesis Inc., the global ... is pleased to announce the appointment of Dr. ... its Board of Directors and Chairman of Advisory ... life science companies to manage their entire validation ... paper in this process. Furthermore, ValGenesis VLMS enables ...
Breaking Medicine Technology: